The potential of the human CD38-specific antibody daratumumab to improve the antimyeloma effect of novel multidrug therapies including patients refractory to lenalidomide or bortezomib

Autor:	M de Weers, Berris van Kessel, Shulamiet Wittebol, Tuna Mutis, Paul Parren Parren, M S van der Veer, H M Lokhorst, Joost M. Bakker
Rok vydání:	2011
Předmět:	Oncology Cancer Research medicine.medical_specialty Bortezomib business.industry Daratumumab CD38 Pharmacology medicine.disease Malignancy Specific antibody Refractory Internal medicine medicine business Multiple myeloma medicine.drug Lenalidomide
Zdroj:	Journal of Clinical Oncology. 29:e18571-e18571
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2011.29.15_suppl.e18571
Popis:	e18571 Background: Multiple myeloma (MM) represents an incurable malignancy of antibody-producing clonal plasma cells. Over the past decade significant progress has been made in MM treatment using ...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::449c0ec690eeef1b8830240de806e4fa https://doi.org/10.1200/jco.2011.29.15_suppl.e18571 Zobrazit plný text záznamu